Renal Protective Effects of Early Continuous Venovenous Hemofiltration in Rhabdomyolysis: Improved Renal Mitochondrial Dysfunction and Inhibited Apoptosis

Artificial Organs

Volumn 37, Issue 4, 2013, Pages 390-400

  Tang, Wanxin ^a   Chen, Zejun ^b   Wu, Weihua ^c   Qiu, Hongyu ^a   Bo, Hong ^a   Zhang, Ling ^a   Fu, Ping ^a  

^a SICHUAN UNIVERSITY   (China)

^b No 3 People's Hospital of Chengdu   (China)

^c SOUTHWEST MEDICAL UNIVERSITY   (China)

Author keywords

Acute kidney injury; Apoptosis; Continuous venovenous hemofiltration; Mitochondria; Rhabdomyolysis

Indexed keywords

ARTIFICIAL ORGANS; BODY FLUIDS; DEPOSITION; ELECTROPHORESIS; MITOCHONDRIA; MORPHOLOGY; PROTEINS;

ACUTE KIDNEY INJURY; CONTINUOUS VENOVENOUS HEMOFILTRATION; HEMOFILTRATION; INTERLEUKIN6 (IL6); MITOCHONDRIAL DYSFUNCTION; MITOCHONDRIAL FUNCTION; MITOCHONDRIAS; MORPHOLOGICAL CHANGES; RHABDOMYOLYSE; TUMOR NECROSIS FACTORS;

CELL DEATH;

CREATININE; INTERLEUKIN 6; MALONALDEHYDE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTINUOUS HEMOFILTRATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOG; ENZYME LINKED IMMUNOSORBENT ASSAY; LIPID PEROXIDATION; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RENAL PROTECTION; RESPIRATION CONTROL; RHABDOMYOLYSIS; URINE VOLUME; WESTERN BLOTTING;

CANIS FAMILIARIS;

EID: 84875957509     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/j.1525-1594.2012.01574.x     Document Type: Article

References (46)

1. Holt S, Moore K. Pathogenesis of renal failure in rhabdomyolysis: the role of myoglobin. Exp Nephrol 2000;8:72-76.
2. 2, and terminal mitochondrial electron transport. Kidney Int 1997;51:728-738.
3. Paller MS. Hemoglobin- and myoglobin-induced acute renal failure in rats: role of iron in nephrotoxicity. Am J Physiol 1988;255:F539-544.
4. Chander V, Chopra K. Molsidomine, a nitric oxide donor and L-arginine protects against rhabdomyolysis-induced myoglobinuric acute renal failure. Biochim Biophys Acta 2005;1723:208-214.
5. Anderson EJ, Katunga LA, Willis MS. Mitochondria as a source and target of lipid peroxidation products in healthy and diseased heart. Clin Exp Pharmacol Physiol 2012;39:179-193.
6. Barazzoni R, Zanetti M, Cappellari GG, etal. Fatty acids acutely enhance insulin-induced oxidative stress and cause insulin resistance by increasing mitochondrial reactive oxygen species (ROS) generation and nuclear factor-κB inhibitor (IκB)-nuclear factor-κB (NFκB) activation in rat muscle, in the absence of mitochondrial dysfunction. Diabetologia 2012;55:773-782.
7. Cadenas E, Davies KJ. Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med 2000;29:222-230.
8. Chicco AJ, Sparagna GC. Role of cardiolipin alterations in mitochondrial dysfunction and disease. Am J Physiol Cell Physiol 2007;292:C33-44.
9. Verdin E, Hirschey MD, Finley LW, Haigis MC. Sirtuin regulation of mitochondria: energy production, apoptosis, and signaling. Trends Biochem Sci 2010;35:669-675.
10. Ayvaz S, Aksu B, Kanter M, etal. Preventive effects of hyperbaric oxygen treatment on glycerol-induced myoglobinuric acute renal failure in rats. J Mol Histol 2012;43:161-170.
11. Kim YS, Jung MH, Choi MY, etal. Glutamine attenuates tubular cell apoptosis in acute kidney injury via inhibition of the c-Jun N-terminal kinase phosphorylation of 14-3-3. Crit Care Med 2009;37:2033-2044.
12. Plotnikov EY, Chupyrkina AA, Pevzner IB, Isaev NK, Zorov DB. Myoglobin causes oxidative stress, increase of NO production and dysfunction of kidney's mitochondria. Biochim Biophys Acta 2009;1792:796-803.
13. Vuletich JL, Osawa Y, Aviram M. Enhanced lipid oxidation by oxidatively modified myoglobin: role of protein-bound heme. Biochem Biophys Res Commun 2000;269:647-651.
14. Burwell LS, Nadtochiy SM, Brookes PS. Cardioprotection by metabolic shutdown and gradual wake-up. J Mol Cell Cardiol 2009;46:804-810.
15. Kim-Shapiro DB, Schechter AN, Gladwin MT. Unraveling the reactions of nitric oxide, nitrite, and hemoglobin in physiology and therapeutics. Arterioscler Thromb Vasc Biol 2006;26:697-705.
16. Ghafourifar P, Schenk U, Klein SD, Richter C. Mitochondrial nitric-oxide synthase stimulation causes cytochrome c release from isolated mitochondria. Evidence for intramitochondrial peroxynitrite formation. J Biol Chem 1999;274:31185-31188.
17. Brune B. Nitric oxide: NO apoptosis or turning it ON? Cell Death Differ 2003;10:864-869.
18. Plotnikov EY, Chupyrkina AA, Jankauskas SS, etal. Mechanisms of nephroprotective effect of mitochondria-targeted antioxidants under rhabdomyolysis and ischemia/reperfusion. Biochim Biophys Acta 2011;1812:77-86.
19. Nicolau D, Feng YS, Wu AHB, Bernstein SP, Nightingale CH. Myoglobin clearance during continuous veno-venous hemofiltration with or without dialysis. Int J Artif Organs 1998;21:205-209.
20. Naka T, Jones D, Baldwin I, etal. Myoglobin clearance by super high-flux hemofiltration in a case of severe rhabdomyolysis: a case report. Crit Care 2005;9:R90-95.
21. Schenk MR, Beck DH, Nolte M, Kox WJ. Continuous veno-venous hemofiltration for the immediate management of massive rhabdomyolysis after fulminant malignant hyperthermia in a bodybuilder. Anesthesiology 2001;94:1139-1141.
22. Amyot SL, Leblanc M, Thibeault Y, Geadah D, Cardinal J. Myoglobin clearance and removal during continuous venovenous hemofiltration. Intensive Care Med 1999;25:1169-1172.
23. Vinay P, Gougoux A, Lemieux G. Isolation of a pure suspension of rat proximal tubules. Am J Physiol 1981;241:F403-411.
24. Tang WX, Wu WH, Zeng XX, Bo H, Huang SM. Early protective effect of mitofusion 2 overexpression in STZ-induced diabetic rat kidney. Endocrine 2012;41:236-247.
25. Cartoni R, Arnaud E, Me'dard J-J, etal. Expression of mitofusin 2R94Q in a transgenic mouse leads to Charcot-Marie-Tooth neuropathy type 2A. Brain 2010;133:1460-1469.
26. 2, and ROS in rats and mice. Chem Biodivers 2010;7:1467-1478.
27. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-358.
28. Natarajan SK, Eapen CE, Pullimood AB, Balasubramanian KA. Oxidative stress in experimental liver microvesicular steatosis: role of mitochondria and peroxisomes. J Gastroenterol Hepatol 2006;21:1240-1249.
29. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
30. Kojic Z, Gopcevic K, Marinkovic D, Tasic G. Effect of captopril on serum lipid levels and cardiac mitochondrial oxygen consumption in experimentally-induced hypercholesterolemia in rabbits. Physiol Res 2011;60(Suppl. 1):S177-184.
31. Zhu T, Au-Yeung KK, Siow YL, Wang G, O K. Cyclosporine a protects against apoptosis in ischemic/reperfused rat kidneys. Clin Exp Pharmacol Physiol 2002;29:852-854.
32. Groebler LK, Liu J, Shanu A, Codd R, Witting PK. Comparing the potential renal protective activity of desferrioxamine B and the novel chelator desferrioxamine B-N-(3-hydroxyadamant-1-yl)carboxamide in a cell model of myoglobinuria. Biochem J 2011;435:669-677.
33. Reeder BJ, Wilson MT. Desferroxamine inhibits production of cytotoxic heme to protein crosslinked myoglobin: a mechanism to protect against oxidative stress without iron chelation. Chem Res Toxicol 2005;18:1004-1011.
34. Chander V, Singh D, Chopra K. Catechin. A natural antioxidant protects against rhabdomyolysis-induced myoglobinuric acute renal failure. Pharmacol Res 2003;48:503-509.
35. Boutaud O, Moore KP, Reeder BJ, etal. Acetaminophen inhibits hemoprotein-catalyzed lipid peroxidation and attenuates rhabdomyolysis-induced renal failure. Proc Natl Acad Sci U S A 2010;107:2699-2704.
36. Sorrentino SA, Kielstein JT, Lukasz A, etal. High permeability dialysis membrane allows effective removal of myoglobin in acute kidney injury resulting from rhabdomyolysis. Crit Care Med 2011;39:184-186.
37. Bellomo R, Daskalakis M, Parkin G, Boyce N. Myoglobin clearance during acute continuous hemodiafiltration. Intensive Care Med 1991;17:509.
38. Goldstein SL. Continuous renal replacement therapy: mechanism of clearance, fluid removal, indications and outcomes. Curr Opin Pediatr 2011;23:181-185.
39. Barenbrock M, Hausberg M, Matzkies F, de la Motte S, Schaefer RM. Effects of bicarbonate- and lactate-buffered replacement fluids on cardiovascular outcome in CVVH patients. Kidney Int 2000;58:1751-1757.
40. Bastani B, Frenchie D. Significant myoglobin removal during continuous veno-venous haemofiltration using F80 membrane. Nephrol Dial Transplant 1997;12:2035-2036.
41. Ronco C. Extracorporeal therapies in acute rhabdomyolysis and myoglobin clearance. Crit Care 2005;9:141-142.
42. Zager RA, Johnson AC. Progressive histone alterations and proinflammatory gene activation: consequences of heme protein/iron-mediated proximal tubule injury. Am J Physiol Renal Physiol 2010;298:F827-837.
43. Hack CE, Aarden LA, Thijs LG. Role of cytokines in sepsis. Adv Immunol 1997;66:101-195.
44. LaMarre J, Wollenberg GK, Gonias SL, Hayes MA. Biology of disease: cytokine binding and clearance properties of proteinase-activated alpha 2-macroglobulin. Lab Invest 1991;65:3-14.
45. Cole L, Bellomo R, Davenport P, Tipping P, Ronco C. Cytokine removal during continuous renal replacement therapy: an ex vivo comparison of convection and diffusion. Int J Artif Organs 2004;27:388-397.
46. Zager RA, Johnson AC, Hanson SY. Proximal tubular cytochrome c efflux: determinant, and potential marker, of mitochondrial injury. Kidney Int 2004;65:2123-2134.